Categories AlphaGraphs, Earnings, Other Industries

New products drive sales at Abbott in Q1

Healthcare company Abbott Laboratories (ABT) reported worldwide sales of $7.4 billion for the first quarter of 2018, an increase of 16.7% versus the prior-year period, helped by new product launches.

Net earnings on a GAAP basis came in at $418 million or $0.23 per share, down slightly from the prior-year quarter. On an adjusted basis, EPS was $0.59.

Despite beating market expectations for sales and earnings, shares dipped slightly in premarket trade.

Worldwide sales in the Nutrition segment increased 7% while sales in the Diagnostics segment grew 58.7% during Q1 2018. Established Pharmaceuticals sales rose 9.9%, while Medical Devices sales improved 14.6% compared to last year.

The Medical devices segment saw good growth during the quarter, benefiting from the St. Jude Medical acquisition. Abbott’s FreeStyle Libre glucose monitoring system helped boost sales in the Diabetes Care division.

In January, Abbott received FDA approval for magnetic resonance (MR)-conditional labeling for its Quadra AssuraTM and Quadra Assura MPTM cardiac resynchronization therapy defibrillator devices and its Fortify AssuraTM implantable cardioverter defibrillator.

For full-year 2018, Abbott estimates GAAP diluted EPS from continuing operations will be in the range of $1.23 to $1.33. Adjusted diluted EPS from continuing operations is projected to range between $2.80 and $2.90.

For the second quarter of 2018, GAAP diluted EPS from continuing operations is expected to be $0.33 to $0.35. Meanwhile, the company anticipates adjusted diluted EPS from continuing operations of between $0.70 and $0.72 during this period.

Abbott Q1 2018 earnings

 

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top